Sage Journals: Discover world-class research

Abstract

Hemophilia has evolved from an often fatal hereditary bleeding disorder to a disorder for which safe and effective treatment is available. However, there are several challenges remaining in the treatment of hemophilia. Prophylaxis to prevent bleeding is costly and requires frequent intravenous injections, which are cumbersome for patients. Venous access is often difficult to achieve, especially in small children where central venous lines may need to be implanted. Development of inhibitory antibodies makes treatment of acute bleeds difficult and prophylaxis in patients with inhibitors must also be better addressed. In order to improve treatment, new products are being developed, some of which are already in clinical trials. There are several approaches to prolonging half-lives such as PEGylation, Fc fusion and albumin fusion. Increased activity has been demonstrated in preclinical trials for factor IX and in a human trial with factor VII where the activity of the molecules has been increased by manipulation of the molecular composition. Additional approaches, including blockage of inhibitors of clotting, are also under investigation. Factor VIII and factor IX gene therapy have become a tangible possibility since phase I data recently have been published. Results are promising and there is hope that in the near future substantial progress will be made, perhaps making hemophilia the first genetic condition to be cured.

Keywords

coagulation hemophilia factor VIII factor IX treatment

Introduction

Hemophilia A and B are hereditary X-chromosomal recessive disorders caused by deficiency or absence of coagulation factors VIII (FVIII) or IX (FIX), respectively. The incidence of hemophilia is commonly reported as 1 in 5000 male births or 1 in 10,000 of the general population. Hemophilia A is four times more common than hemophilia B. The disorders are classified according to the coagulation factor activity (FVIII:C or FIX:C, respectively) present in blood with three categories comprising severe (<1% of normal activity), moderate (1–5%) or mild (>5% to <40%) [White et al. 2001]. Although these categories define overall bleeding manifestations, the clinical phenotype may vary within each group. Mild hemophilia can go unnoticed depending on the level of deficiency and the stressors the individual experiences, therefore the proportion of cases of mild hemophilia that are registered may vary [Larsson, 1984; Soucie et al. 2000]. Severe hemophilia is characterized by spontaneous joint, muscle, gastrointestinal and central nervous system (CNS) bleeding resulting in substantial morbidity and even mortality. Treatment of hemophilia is based on replacing the missing factor with concentrates containing FVIII or FIX. Mild hemophilia A can usually be treated with desmopressin, thereby increasing the levels of the patient’s own FVIII [Mannucci, 2008]. Long-term prophylaxis is becoming widely used in severe forms of hemophilia [Ljung, 2009]. Clotting factors and replacement strategies continue to evolve, mainly for patients without inhibitory antibodies to the missing factor. For patients with inhibitors, treatment for acute bleeding episodes, immune tolerance and, sometimes, immune modulation for inhibitor reduction, are available. In addition, adjuvant therapies such as desmopressin, antifibrinolytics and topical agents contribute to treatment of bleeding in many patients. Cloning of the genes for FVIII and FIX, which occurred over 20 years ago, revolutionized the therapy of both hemophilia A and B. A high proportion of the therapy used today in resource strong countries is recombinant factor concentrates. Initial development of recombinant FVIII was optimized by the co-expression of von Willebrand factor (VWF) that enhances the intracellular trafficking and folding of FVIII. Expression systems that produce FVIII in which the B domain has essentially been removed have been important for production efficiency and also for the early gene therapy attempts since, for most vectors, the size of full-length FVIII is problematic. Recombinant FIX, although clinically effective and with the same half-life as plasma products, has some variability in posttranslational processing which may be the cause of the lower in vivo recovery compared with plasma-derived products. Recombinant activated factor VII (rFVIIa) is used to treat patients with hemophilia who have developed inhibitory antibodies. Given the likely addition of new long-acting/long-circulating clotting factors, hemostatic agents that block tissue factor pathway inhibitor (TFPI) and gene therapies, such as gene transfer and premature termination codon suppressors, the future of hemophilia care looks very promising. To understand the forces that drive the development of new treatments in hemophilia, it is important to be knowledgeable about current use of and development of treatments.

Current treatment

Prophylaxis is used in countries that can support the associated medical costs and that give priority to hemophilia care. Prophylactic treatment began in Sweden during the 1950s; a 25-year follow-up of 60 patients was subsequently published in 1992 [Nilsson et al. 1992]. The Netherlands also has a long history of use of prophylactic regimens [Van Creveld, 1969, 1971a, 1971b]. The Dutch strategy has differed from the Swedish, primarily with respect to later time of start, lower dosing, and longer dose intervals resulting in less costly regimens [van den Berg et al. 2001]. Whereas the Swedish regimen has been relatively fixed, aiming at a trough level of 1% or greater, the Dutch regimen has been tailored to the individual bleeding phenotype.

The trend in Europe is administration of primary prophylaxis [Chambost and Ljung, 2005]. This strategy has been recommended as the standard of care by the Medical and Scientific Advisory Council of the National Hemophilia Foundation, the World Federation of Hemophilia and the World Health Organization [Rodriguez and Hoots, 2010]. It is clear that early start is important as an independent predictor of future joint disease [Astermark et al. 1999; Funk et al. 1998; Kreuz et al. 1998; Petrini et al. 1991]. The challenge with early initiation at the age of 1–2 years remains one of venous access, often requiring the use of a central venous catheter [Ljung, 2002; Petrini et al. 2004; Van den Berg et al. 2006; Yee et al. 2002]. Several authors have recommended beginning therapy with a once-weekly infusion to decrease the need for these devices, and because of the substantial variability of clinical phenotype in severe hemophilia [Aledort et al. 1994; Escuriola Ettingshausen et al. 2001; Feldman et al. 2006; van Dijk et al. 2005]. In clinical practice, most prophylactic regimens are tailored to the need of the individual patient. Methods to develop individualized regimens have included use of pharmacokinetic data and computer-simulated dose level and interval to achieve a predetermined trough level [Carlsson et al. 1993, 1998]. Decreasing intervals between prophylactic doses from 2–3 infusions weekly to every other day theoretically reduces average FVIII consumption by 43% with maintained or increased trough FVIII levels, while daily dosing would reduce mean FVIII usage by 82%. A modified dosage regimen with infusions every other day was implemented in a group of Swedish patients with data obtained supporting the pharmacokinetic models [Carlsson et al. 1993]. Patients who have experienced joint bleeds may, in addition to the treatment of bleeds, be treated with periodic use of factor concentrates. This approach is known as secondary prophylaxis and is commonly used to minimize bleeding frequency and minimize the progression of joint disease. Secondary prophylaxis cannot reverse, but can decrease the progression of chronic arthropathy. It reduces the frequency of bleeding, hospital admissions and lost days from school or work. The use of secondary prophylaxis versus on-demand therapy has been studied in children and adults, the results indicating that secondary prophylaxis results in a decreased number of joint bleedings [Aledort et al. 1994; Smith et al. 1996; Szucs et al. 1998]

Inhibitors develop in approximately 30% of patients with severe hemophilia A and are less common, ~5%, in those with severe hemophilia B [Astermark, 2006]; a broad range of inhibitor incidence/prevalence has been reported among different studies. A variety of factors may impact inhibitor development including but not limited to: type of hemophilia, level of deficiency, specific genetic mutation, race, immune response genes, and environmental influences. Among environmental issues suggested are the type of clotting factor therapy utilized, such as plasma derived versus recombinant, intermediate versus high-purity products, treatment regimen (prophylaxis versus on-demand), peak treatments and age at start of treatment, etc. [Calvez and Laurian, 2006; Gouw et al. 2007b; Santagostino et al. 2005].

During recent years, there has been discussion as to whether recombinant products are more immunogenic than plasma-derived intermediate purity products, especially those with intact von Willebrand factor (VWF) [Goudemand et al. 2006; Gouw et al. 2007a; Iorio et al. 2010; Scharrer et al. 1999]. Preclinical research addressing of if and how vWF or other proteins regulate the immune response have been published [Dasgupta et al. 2007; Qadura et al. 2009]. Despite active debate regarding this issue, the currently available support for either position is of relatively low scientific value: no prospective randomized study has been performed to address the issue. A recent European consensus report stated that there is no difference in risk of inhibitor development between different concentrate types [Astermark et al. 2006]. The question regarding type of concentrate and rate of inhibitor development are being addressed by collection of registry data such as the EUHASS registry [Makris et al. 2011] and by the SIPPET study, where classes of products are being compared in a randomized prospective fashion [Mannucci et al. 2007].

The most important issues with respect to hemophilia treatment are use of prophylaxis, and inhibitor development:

Treatment with factor concentrates requires intravenous injections, a burden that negatively impacts quality of life. As prophylaxis should be started early [Astermark et al. 1999] small children are in need of ports to provide venous access, requiring a surgical procedure early in life with its general risks, and, in addition, surgical procedures may be a risk factor for inhibitor development [Gouw et al. 2007b]. Ports are a source for septic infections [Ljung et al. 1992]. Novel products with longer biological half-life have a potential to increase convenience and reduce the need for port implantations. Such products are now in clinical trials.

Inhibitor risk is associated with genetic factors [Astermark, 2006] especially the disease causative mutation [Oldenburg et al. 2002]. This means that treatment with FVIII in a patient with a high-risk mutation has a substantial risk for development of an inhibitor. Methods for avoidance of inhibitors remain an important, but unmet, need. There are clinical trials attempting to address this with currently available products. One, for example, controls the treatment regimen by early start of prophylaxis in relatively low doses [ClinicalTrials.gov identifier: NCT01376700]. A logical rationale would be to treat individuals at high risk with products not recognized as FVIII by the immune system. Such products are in early development. In summary, the possibility to predict development of an inhibitor, and learn to avoid this, remain to be elucidated.

Patients having high-titer inhibitors cannot be treated using FVIII replacement therapy. Therefore, bypassing products have been used for many years. The currently available products are rFVIIa and activated prothrombin complex concentrate (aPCC). These drugs are very different in terms of content and mode of action, but seem to have rather similar overall effectiveness with regard to treatment of acute bleeds [Astermark et al. 2007] with efficacy rates of the order of 80–90% [Astermark et al. 2006], leaving a proportion of patients without effective treatment. Obviously, there is a need for products that can promote and predict hemostasis in a secure way when an inhibitor is present. New products for this patient group are under development, and molecules with increased activity are in clinical trials. Prophylactic therapy for this patient group would be a step forward; studies are being undertaken for this purpose with new molecules.

New products and approaches to treatment

New, improved products or treatment approaches for hemophilia A or B would significantly improve the lives of patients. Current therapy is cumbersome and intermittent, due to the need of intravenous injections, with peaks and troughs in plasma factor levels allowing for breakthrough bleeding episodes. Both FVIII and FIX have wide therapeutic windows and slight increases in factor levels will reduce morbidity. Treatment that provides more ‘close to normal’ levels would allow a lifestyle similar to people without a bleeding disorder. The most well-known techniques for new products are described and summarized in Table 1. Information provided has been obtained from ClinicalTrials.gov.

Table 1.

Currently ongoing product development.

Technique used	Product	Published clinical results hemophilia indication	Clinical studies	ClinicalTrials.gov identifier
PEGylation	FVIII	No	2 Phase 1/II compl., Phase III open	NCT01184820, NCT01205724, NCT01480180
	FIX	Yes [Negrier et al. 2011]	Phase 1/II compl., Phase III open	NCT00956345, NCT01333111
	FVIIa	Yes [Moss et al. 2011]	Phase 1 compl., Phase II compl.	NCT00922792, NCT00951405
PEGylated liposomes	FVIII	Yes [Spira et al. 2006, 2008, 2010]	Phase III and project closed due to lack of efficacy	NCT00245297, NCT00629837, NCT00623727
Polysialic acid	FVIII	No	-	-
Albumin fusion	FVIIa	No	-	-
	FIX	No	Phase I ongoing	NCT01361126, NCT01233440
Fc fusion	FVIII	No	Phase 1/II compl., Phase III compl.	NCT01027377
	FIX	Yes [Shapiro et al. 2011]	Phase 1/II compl., Phase III compl.	NCT00716716
Increased activity	FVIIa	Yes [Moss et al. 2009]	Phase I and II compl. Phase III ongoing	NCT00486278, NCT01392547
Gene therapy	FVIII	Yes, reviewed by Pierce et al. [2007]	Two phase I trials ongoing	NCT00979238, NCT00515710
	FIX
Anti-TFPI	antibody	No	Phase I ongoing	NCT01228669
	aptamer	No	Phase I registered	NCT01191372
Read-through of premature stop codons	Hemophilia A or B	No	Phase II study suspended	NCT00947193
Transgenic animals	FVIII	No	-	-
	FIX
Transgenic tobacco plants	FIX	No	-	-

TFPI, tissue factor pathway inhibitor

PEGylation

PEGylation is an established method for prolonging the half-life of protein products and it has successfully been used in several therapeutic proteins [Fried et al. 2002; Keating and Curran, 2003]. The volume of PEGylated proteins is increased, leading to reduced renal clearance and shielding effects may diminish receptor mediated clearance, susceptibility to proteolytic degradation and reduction in immunogenicity [Webster et al. 2007]. For FVIII but maybe not for FIX, PEGylation is likely to have more limited advantage compared with other biologics, as the FVIII molecule is large enough not to be filtered by the kidney. Instead, PEGylation may reduce interaction with clearance receptors in the liver. Another benefit could be reduction of contact with inactivating proteases and immune-mediating cells. Variants have been engineered with a polyethylene glycol (PEG) polymer specifically conjugated to parts of the molecule and preclinical data are published from two groups using different approaches [Holmberg et al. 2009; Mei et al. 2010; Ostergaard et al. 2011]. In bleeding models of hemophilic mice, PEGylated FVIII not only exhibited prolonged efficacy that is consistent with the improved pharmacokinetics but also showed efficacy in stopping acute bleeds comparable with that of unmodified rFVIII [Mei et al. 2010]. The same has been shown for PEGylated FIX [Holmberg et al. 2009; Ostergaard et al. 2011]. Clinical trials with PEGylated FVIII and FIX have been initiated. So far, data from one FIX phase I/II trial have been published showing a half-life of 93 hours, five times greater than previous products [Negrier et al. 2011], and a phase III trial is ongoing [ClinicalTrials.gov identifier: NCT01333111]. Two phase I/II trials with PEGylated FVIII, from different companies, have been completed and one phase III trial initiated [ClinicalTrials.gov identifier: NCT01480180]. PEGylated FVIIa has also been developed to meet the need of prophylactic therapy for inhibitor patients. A phase I trial has been published [Moss et al. 2011] and a phase II trial in patients has been completed [ClinicalTrials.gov identifier: NCT00951405]. In the case of FVIIa the PEG is attached to the active molecule and not attached to the zymogen and cleaved off when activated as done for FVIII and FIX

The use of PEGylated liposomes has also been tried in humans [Spira et al. 2010].

Liposomes can be efficacious vehicles for medicines, and surface modification by PEGylation can prolong liposome circulation time. Use of this preparation was associated with increased protection from bleeding [Spira et al. 2006]. The product (KG-Lip) was further evaluated in a large clinical trial, the Liplong study, where once-a-week treatment with the product was compared with Kogenate FS Bayer. The study was stopped because the KG-Lip product failed to meet the endpoints and was inferior to the comparator product which was given three times per week.

Fc fusion

Fc fusion, the neonatal Fc receptor (FcRn), is a MHC class I like molecule that functions to protect IgG and albumin from catabolism, mediates transport of IgG across epithelial cells, and is involved in antigen presentation by professional antigen presenting cells. The ability of this receptor to prolong the half-life of IgG and albumin has guided development of novel therapeutics [Kuo et al. 2010]. Peters and colleagues have summarized studies in which Fc has been fused to FIX [Peters et al. 2010]. Taken together, these studies showed the enhanced pharmacodynamic and pharmacokinetic properties of the rFIXFc fusion protein and provided the basis for evaluating rFIXFc in patients with hemophilia B. A recombinant fusion protein (rFIXFc) containing a single FIX molecule attached to the Fc region of immunoglobulin G was administered intravenously and found to have an extended half-life, compared with recombinant FIX (rFIX) in hemophilia patients. The phase I trial has been completed for rFIXFc [ClinicalTrials.gov identifier: NCT00716716] and published results showed an approximate threefold increased half-life compared with current products [Shapiro et al. 2011]. Recruitment in the FVIII phase I trial is also completed [ClinicalTrials.gov identifier: NCT01027377]. Clinical trials (phase II/III) in patients with hemophilia A and B are fully recruited or completed and results will soon be published.

Albumin fusion

Albumin has a long half-life, exceeding 20 hours. As albumin is a product with a strong safety record, and does not appear to be immunogenic, it presents an option for extension of clotting factor half-life using genetic fusion. Weimer and colleagues reported a recombinant FVIIa molecule with an extended half-life based on genetic fusion to human albumin [Weimer et al. 2008]. The recombinant FVII albumin fusion protein (rVII-FP) was expressed in mammalian cells and upon activation displayed a FVII activity close to that of wild type FVIIa. Pharmacokinetic studies in rats demonstrated that the half-life of the activated recombinant FVII albumin fusion protein (rVIIa-FP) was extended compared with wild-type rFVIIa. Albumin has also been fused to FIX and two phase I/II trials are currently registered [ClinicalTrials.gov identifiers: NCT01361126 and NCT01233440]. Results are not yet available.

Increased activity of molecules

It has been possible to increase the catalytic activity of FIX using different techniques: replacing the epidermal growth factor (EGF)-like domain of FIX with that of FVII [Chang et al. 1997] or changing residue 338 in human FIX from arginine to alanine [Chang et al. 1998]. Intensifying the catalytic activity has an obvious potential to construct a drug which is more efficacious for treatment of hemophilia B, but to date the concept has not been tested in human trials. For FVII the progress has come further, although much information is available only in abstract form, and clinical trials are ongoing or planned. Novo Nordisk A/S as well as Bayer Healthcare have developed FVIIa molecules with increased activity compared with the currently available product (NovoSeven®, Novo Nordisk A/S). The rFVIIa analog (NN1731, Novo Nordisk A/S) has three amino-acid substitutions that stabilize the molecule in its active conformation in the absence of tissue factor. Preclinical data indicate that compared with rFVIIa the analog has a more rapid onset of action, forms a stronger clot that is more resistant to fibrinolysis and exhibits an improved therapeutic window [Allen et al. 2007; Holmberg et al. 2009; Sorensen et al. 2007]. The product has been administered to healthy subjects [Moss et al. 2009], a phase II trial in patients has been completed [ClinicalTrials.gov identifier: NCT00486278] and the phase III trial is recruiting [ClinicalTrials.gov identifier: NCT01392547]. Results of clinical trials must be completed before the future of these products can be evaluated. There is a need for more efficacious products to treat bleeds in inhibitor patients and perhaps also for prophylaxis. Safety aspects are important and the potential increased risk of thromboembolism needs to be carefully evaluated.

Polysialic acid

Polysialic acid (PSA) is an anionic moiety that adds multiple negative charges to the protein thereby changing its surface charge and binding capabilities [Pisal et al. 2010]. PSA is thought to be able to interfere with receptor-mediated clearance processes of FVIII. The compound is under preclinical evaluation, and no data available at this time.

Gene therapy

Hemophilia is an attractive disease for gene therapy for many reasons. It is a relatively prevalent disorder compared with many monogenetic disorders and the functions of the missing proteins are well studied. Both FVIII and FIX have wide therapeutic windows and slight increases in factor levels will reduce morbidity. Endogenous FVIII and FIX are secreted by endothelial cells and hepatocytes but can be expressed in other types of cells, thereby increasing the options for gene transfer. Five gene transfer phase I clinical trials have been conducted using either direct in vivo gene delivery with viral vectors or ex vivo plasmid transfections and reimplantation of gene-engineered cells [Pierce et al. 2007]. Although there was evidence of gene transfer and therapeutic effects in some of these trials, stable expression of therapeutic FVIII or FIX levels has not yet been obtained. Further improvements of the vectors and a better understanding of the immune consequences of gene transfer are warranted and ongoing. There are two phase I/II gene therapy trials in hemophilia B registered [ClinicalTrials.gov identifiers: NCT00979238 and NCT00515710]. The publication of a successful gene therapy approach in adenosine deaminase-deficient severe combined immunodeficiency (SCID) patients [Aiuti et al. 2009] and the recent publication of gene transfer in hemophilia B [Nathwani et al. 2011] provides hope that gene therapy is a possibility.

Blockade of tissue factor pathway inhibitor

Blockade of an inhibitor of clotting, tissue factor pathway inhibitor (TFPI) is another interesting approach. A class of therapeutics that is being investigated is the nonanticoagulant sulphated polysaccharides (NASP). They are believed to act through blockade of TFPI. NASP can accelerate the clotting times of plasma from hemophilia patients, improve hemostasis when administered subcutaneously to hemophilic mice [Liu et al. 2006] and improve hemostasis when administered orally to severe hemophilia A dogs [Prasad et al. 2008]. A new technology, aptamers, which are single-stranded nucleic acids, can also be used to block TFPI. Aptamers directly inhibit function by folding into a specific structure with high affinity for the target [White et al. 2000]. This technology is being explored in clinical trials of other disorders and a trial with an anti-TFPI–aptamer is registered although not yet recruiting [ClinicalTrials.gov identifier: NCT01191372]. An anti-TFPI antibody is in a phase I clinical trial [ClinicalTrials.gov identifier: NCT01228669]; no data are available as of yet.

Other approaches

Some of the mutations causing hemophilia are nonsense changes. Small molecules have been developed that can read-through premature stop codons. Ataluren (PTC124) is an orally delivered, investigational drug that acts to overcome the effects of the premature stop codon [Hirawat et al. 2007; Welch et al. 2007], potentially enabling the production of functional FVIII/FIX [ClinicalTrials.gov identifier: NCT00947193]. The study was suspended, no reason was given. Another approach is to develop pharmaceuticals using transgenic animals and plants. Both FVIII and FIX have been produced in transgenic pigs as bioreactors [Paleyanda et al. 1997; Pipe et al. 2011; Van Cott et al. 1999] and FIX in chloroplast transgenic tobacco plants [Verma et al. 2010]

Concluding remarks

The advantage of long-acting products or gene therapy is obvious. A reduction of intravenous punctures is especially important for pediatric patients. Less frequent need for venous access means fewer placements of indwelling catheters. Furthermore, frequent dosing interrupts daily activities and many patients must rely on help from family or sometimes even hospital personnel. Compliance with frequent injection regimens is one of the most commonly cited reasons for failure of prophylaxis [Geraghty et al. 2006]. In addition, a single dose may be sufficient for intensive treatment of a bleeding episode, which would be an advantage especially for patients that must travel for help with injections. A concern related to the half-life of the product and how seldom it is dosed, is that the factor levels in plasma, although measurable, could be rather low during a substantial number of hours. Given the broad variation in clinical phenotype, some patients are at risk of bleeding at FVIII/FIX levels which exceed those that may be obtained with some products during a substantial portion of the week [Ahnstrom et al. 2004]. This fear is even more relevant if the patient is physically active, involved in sports, etc. Therefore, extra doses of concentrate may be needed prior to activity. This could be an extra dose with a product with shorter half-life: an approach similar to that used for insulin treatment. However, this approach for hemophilia can only be considered second best since, if possible, at an acceptable cost, there is no known disadvantage to continuously have 50–80% of normal FVIII or FIX activity levels.

The advent of more potent bypassing products opens up the possibility of treating acute bleeds better and more reliably. A more potent and perhaps longer-acting bypassing agent could open the possibilities for efficacious prophylaxis for patients with inhibitors. Anti-TFPI, which perhaps could be administered subcutaneously or orally, is another possibility for this patient group. As inhibitors develop early in life, institution of effective prophylaxis could be a reality before the onset of joint disease, as is the case in children without inhibitors, i.e. as primary prophylaxis.

Development of an inhibitor is a major concern and threat to the health of the person with hemophilia. If a reliable mechanism, such as a score for predicting inhibitor risk could be developed, new products or new treatment regimens could hypothetically be used to avoid challenges to the immune system in such patients. An example would be to give biosuperior FVIIa or anti-TFPI to patients with hemophilia A and a very high risk score for developing an inhibitor. So far such attempts however do not seem to have been successful [Rivard et al. 2005]. The future will tell us whether such approaches will become reality.

Footnotes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

Erik Berntorp has received speakers fees and is on the Advisory Boards of Baxter BioScience, Novo Nordisk. Bayer, Pfizer, CSL Behring, Biogen-Idec Pharmaceuticals and Octapharma. Karin Knobe has previoulsly been employed by Novo Nordisk.

References

Ahnstrom

Berntorp

Lindvall

Bjorkman

(2004) A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 10: 689–697.

Aiuti

Cattaneo

Galimberti

Benninghoff

Cassani

Callegaro

. (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447–458.

Aledort

L.M.

Haschmeyer

R.H.

Pettersson

(1994) A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 236: 391–399.

Allen

G.A.

Persson

Campbell

R.A.

Ezban

Hedner

Wolberg

A.S.

(2007) A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 27: 683–689.

Astermark

(2006) Overview of inhibitors. Semin Hematol 43(2 Suppl. 4): S3–S7.

Astermark

Morado

Rocino

van den Berg

H.M.

von Depka

Gringeri

. (2006) Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 12: 363–371.

Astermark

Petrini

Tengborn

Schulman

Ljung

Berntorp

(1999) Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 105: 1109–1113.

Astermark

Rocino

Von Depka

Van Den Berg

H.M.

Gringeri

Mantovani

L.G.

. (2007) Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 13: 38–45.

Calvez

Laurian

(2006) Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required. Br J Haematol 132: 798–800; author reply 800–791.

10.

Carlsson

Berntorp

Bjorkman

Lindvall

(1993) Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 51: 247–252.

11.

Carlsson

Bjorkman

Berntorp

(1998) Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 4(2): 83–88.

12.

Chambost

Ljung

(2005) Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 11(2): 92–99.

13.

Chang

Jin

Lollar

Bode

Brandstetter

Hamaguchi

. (1998) Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 273: 12089–12094.

14.

Chang

J.Y.

Monroe

D.M.

Stafford

D.W.

Brinkhous

K.M.

Roberts

H.R.

(1997) Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest 100: 886–892.

15.

Dasgupta

Repesse

Bayry

Navarrete

A.M.

Wootla

Delignat

. (2007) VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 109: 610–612.

16.

Escuriola Ettingshausen

Halimeh

Kurnik

Schobess

Wermes

Junker

. (2001) Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 85: 218–220.

17.

Feldman

B.M.

Pai

Rivard

G.E.

Israels

Poon

M.C.

Demers

. (2006) Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 4: 1228–1236.

18.

Fried

M.W.

Shiffman

M.L.

Reddy

K.R.

Smith

Marinos

Goncales

F.L.

Jr. . (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.

19.

Funk

Schmidt

Escuriola-Ettingshausen

Pons

Dzinaj

Weimer

. (1998) Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol 77: 171–174.

20.

Geraghty

Dunkley

Harrington

Lindvall

Maahs

Sek

(2006) Practice patterns in haemophilia A therapy — global progress towards optimal care. Haemophilia 12(1): 75–81.

21.

Goudemand

Rothschild

Demiguel

Vinciguerrat

Lambert

Chambost

. (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107: 46–51.

22.

Gouw

S.C.

van der Bom

J.G.

Auerswald

Ettinghausen

C.E.

Tedgard

van den Berg

H.M.

(2007a) Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109: 4693–4697.

23.

Gouw

S.C.

van der Bom

J.G.

Marijke van den Berg

(2007b) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109: 4648–4654.

24.

Hirawat

Welch

E.M.

Elfring

G.L.

Northcutt

V.J.

Paushkin

Hwang

. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47: 430–444.

25.

Holmberg

H.L.

Lauritzen

Tranholm

Ezban

(2009) Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 7: 1517–1522.

26.

Iorio

Halimeh

Holzhauer

Goldenberg

Marchesini

Marcucci

. (2010) Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 8: 1256–1265.

27.

Keating

G.M.

Curran

M.P.

(2003) Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63: 701–730.

28.

Kreuz

Escuriola-Ettingshausen

Funk

Schmidt

Kornhuber

(1998) When should prophylactic treatment in patients with haemophilia A and B start?—The German experience. Haemophilia 4: 413–417.

29.

Kuo

T.T.

Baker

Yoshida

Qiao

S.W.

Aveson

V.G.

Lencer

W.I.

. (2010) Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 30: 777–789.

30.

Larsson

S.A.

(1984) Hemophilia in Sweden. Studies on demography of hemophilia and surgery in hemophilia and von Willebrand’s disease. Acta Med Scand Suppl 684: 1–72.

31.

Liu

Scallan

C.D.

Broze

G.J.

Jr Patarroyo-White

Pierce

G.F.

Johnson

K.W.

(2006) Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP). Thromb Haemost 95: 68–76.

32.

Ljung

(2009) Prophylactic therapy in haemophilia. Blood Rev 23: 267–274.

33.

Ljung

Petrini

Lindgren

A.K.

Berntorp

(1992) Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 81: 918–920.

34.

Ljung

R.C.

(2002) Aspects of haemophilia prophylaxis in Sweden. Haemophilia 8(Suppl. 2): 34–37.

35.

Makris

Calizzani

Fischer

Gilman

E.A.

Hay

C.R.

Lassila

. (2011) EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 127(Suppl. 2): S22–S25.

36.

Mannucci

P.M.

(2008) Desmopressin: an historical introduction. Haemophilia 14(Suppl. 1): 1–4.

37.

Mannucci

P.M.

Gringeri

Peyvandi

Santagostino

(2007) Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 13(Suppl. 5): 65–68.

38.

Mei

Pan

Jiang

Tjandra

Strauss

Chen

. (2010) Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 116: 270–279.

39.

Moss

Rosholm

Lauren

(2011) Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 9: 1368–1374.

40.

Moss

Scharling

Ezban

Moller Sorensen

(2009) Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost 7: 299–305.

41.

Nathwani

A.C.

Tuddenham

E.G.

Rangarajan

Rosales

McIntosh

Linch

D.C.

. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357–2365.

42.

Negrier

Knobe

Tiede

Giangrande

Moss

(2011) Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 118: 2695–2701.

43.

Nilsson

I.M.

Berntorp

Lofqvist

Pettersson

(1992) Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232: 25–32.

44.

Oldenburg

El-Maarri

Schwaab

(2002) Inhibitor development in correlation to factor VIII genotypes. Haemophilia 8(Suppl. 2): 23–29.

45.

Ostergaard

Bjelke

J.R.

Hansen

Petersen

L.C.

Pedersen

A.A.

Elm

. (2011) Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 118: 2333–2341.

46.

Paleyanda

R.K.

Velander

W.H.

Lee

T.K.

Scandella

D.H.

Gwazdauskas

F.C.

Knight

J.W.

. (1997) Transgenic pigs produce functional human factor VIII in milk. Nat Biotechnol 15: 971–975.

47.

Peters

R.T.

Low

S.C.

Kamphaus

G.D.

Dumont

J.A.

Amari

J.V.

. (2010) Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 115: 2057–2064.

48.

Petrini

Chambost

Nemes

(2004) Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary. Haemophilia 10(Suppl. 4): 94–96.

49.

Petrini

Lindvall

Egberg

Blomback

(1991) Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 13: 280–287.

50.

Pierce

G.F.

Lillicrap

Pipe

S.W.

Vandendriessche

(2007) Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost 5: 901–906.

51.

Pipe

S.W.

Miao

Butler

S.P.

Calcaterra

Velander

W.H.

(2011) Functional factor VIII made with von Willebrand factor at high levels in transgenic milk. J Thromb Haemost 9: 2235–2242.

52.

Pisal

D.S.

Kosloski

M.P.

Balu-Iyer

S.V.

(2010) Delivery of therapeutic proteins. J Pharm Sci 99: 2557–2575.

53.

Prasad

Lillicrap

Labelle

Knappe

Keller

Burnett

. (2008) Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 111: 672–679.

54.

Qadura

Waters

Burnett

Chegeni

Bradshaw

Hough

. (2009) Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 114: 871–880.

55.

Rivard

G.E.

Lillicrap

Poon

M.C.

Demers

Lepine

St-Louis

. (2005) Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age? Haemophilia 11: 335–339.

56.

Rodriguez

N.I.

Hoots

W.K.

(2010) Advances in hemophilia: experimental aspects and therapy. Hematol Oncol Clin North Am 24: 181–198.

57.

Santagostino

Mancuso

M.E.

Rocino

Mancuso

Mazzucconi

M.G.

Tagliaferri

. (2005) Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 130: 422–427.

58.

Scharrer

Bray

G.L.

Neutzling

(1999) Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5: 145–154.

59.

Shapiro

A.D.

Ragni

M.V.

Valentino

L.A.

Key

N.S.

Josephson

N.C.

Powell

J.S.

. (2011) Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood, in press.

60.

Smith

P.S.

Teutsch

S.M.

Shaffer

P.A.

Rolka

Evatt

(1996) Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 129: 424–431.

61.

Sorensen

Persson

Ingerslev

(2007) Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 137: 158–165.

62.

Soucie

J.M.

Nuss

Evatt

Abdelhak

Cowan

Hill

. (2000) Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 96: 437–442.

63.

Spira

Plyushch

Zozulya

Yatuv

Dayan

Bleicher

. (2010) Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII—an open label, exploratory, cross-over, phase I/II study. Haemophilia 16: 910–918.

64.

Spira

Plyushch

O.P.

Andreeva

T.A.

Andreev

(2006) Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 108: 3668–3673.

65.

Spira

Plyushch

O.P.

Andreeva

T.A.

Khametova

R.N.

(2008) Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 100: 429–434.

66.

Szucs

T.D.

Offner

Kroner

Giangrande

Berntorp

Schramm

(1998) Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group. Haemophilia 4: 498–501.

67.

Van Cott

K.E.

Butler

S.P.

Russell

C.G.

Subramanian

Lubon

Gwazdauskas

F.C.

. (1999) Transgenic pigs as bioreactors: a comparison of gamma-carboxylation of glutamic acid in recombinant human protein C and factor IX by the mammary gland. Genet Anal 15: 155–160.

68.

Van Creveld

(1969) Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 41: 206–214.

69.

Van Creveld

(1971a) Prophylaxis in haemophilia. Lancet 1: 450.

70.

Van Creveld

(1971b) Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 45: 120–127.

71.

Van den Berg

H.M.

Dunn

Fischer

Blanchette

V.S.

(2006) Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy. Haemophilia 12(Suppl. 3): 159–168.

72.

van den Berg

H.M.

Fischer

Mauser-Bunschoten

E.P.

Beek

F.J.

Roosendaal

van der Bom

J.G.

. (2001) Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 112: 561–565.

73.

van Dijk

Fischer

van der Bom

J.G.

Grobbee

D.E.

van den Berg

H.M.

(2005) Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 11: 438–443.

74.

Verma

Moghimi

LoDuca

P.A.

Singh

H.D.

Hoffman

B.E.

Herzog

R.W.

. (2010) Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci U S A 107: 7101–7106.

75.

Webster

Didier

Harris

Siegel

Stadler

Tilbury

. (2007) PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35: 9–16.

76.

Weimer

Wormsbacher

Kronthaler

Lang

Liebing

Schulte

(2008) Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 99: 659–667.

77.

Welch

E.M.

Barton

E.R.

Zhuo

Tomizawa

Friesen

W.J.

Trifillis

. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87–91.

78.

White

G.C.

II Rosendaal

Aledort

L.M.

Lusher

J.M.

Rothschild

Ingerslev

(2001) Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 85: 560.

79.

White

R.R.

Sullenger

B.A.

Rusconi

C.P.

(2000) Developing aptamers into therapeutics. J Clin Invest 106: 929–934.

80.

Yee

T.T.

Beeton

Griffioen

Harrington

Miners

Lee

C.A.

. (2002) Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 8(2): 76–82.

New treatments in hemophilia: insights for the clinician

Abstract

Keywords

Introduction

Current treatment

New products and approaches to treatment

PEGylation

Fc fusion

Albumin fusion

Increased activity of molecules

Polysialic acid

Gene therapy

Blockade of tissue factor pathway inhibitor

Other approaches

Concluding remarks

Footnotes

Funding

Conflict of interest statement

References